Skip to Content
Merck

Key Documents

View All Documentation

S6319

Sertraline hydrochloride

≥98% (HPLC), Selective serotonin reuptake inhibitor (SSRI), powder

Synonym(s):

Sertraline HCl, (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C17H17NCl2 · HCl
CAS Number:
79559-97-0
Molecular Weight:
342.69
UNSPSC Code:
12352200
PubChem Substance ID:
24278601
NACRES:
NA.77
MDL number:
MFCD00895772
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Sertraline hydrochloride, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +33 to +43°, c = 2.0 in methanol

storage condition

desiccated

color

white

solubility

DMSO: >20 mg/mL

SMILES string

ClC1=C(Cl)C=CC([C@H]2C3=C(C=CC=C3)[C@@H](NC)CC2)=C1.[H]Cl

InChI

1S/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H/t12-,17-;/m0./s1

InChI key

BLFQGGGGFNSJKA-XHXSRVRCSA-N

Gene Information

human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363), SLC6A4(6532)

Application

The effect of exposure of sertraline hydrochloride was studied in chronically prepared ovine fetus. It was used in glucocorticoid function assay to study the effect of antidepressants on glucocorticoid receptor function in humans.

Biochem/physiol Actions

Selective serotonin reuptake inhibitor, antidepressant.
Sertraline suppresses platelet function and exhibits antiplatelet and endothelium protective functions. It relieves depression and improves the quality of life in patients with cardiovascular disorders. It can also be prescribed to treat depression in Parkinson′s disease.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Still not finding the right product?

Explore all of our products under Sertraline hydrochloride

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - STOT RE 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000159863
0000450078
0000450080
0000450080
0000450078

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rafael R Domingues et al.
Toxics, 10(1) (2022-01-21)
Selective serotonin reuptake inhibitors (SSRI) are the most common antidepressant used by pregnant women; however, they have been associated with adverse pregnancy outcomes and perinatal morbidity in pregnant women and animal models. We investigated the effects of two SSRI, fluoxetine
Hannah P Fricke et al.
Physiological reports, 11(23), e15881-e15881 (2023-11-30)
At the end of gestation, fetal skeleton rapidly accumulates calcium, and bone development continues in offspring postnatally. To accommodate, maternal skeletal physiology is modulated in a serotonin-dependent manner. Selective serotonin reuptake inhibitors (SSRIs) are generally considered safe for treatment of
Hannah P Fricke et al.
Frontiers in pharmacology, 14, 1244580-1244580 (2023-12-11)
Postpartum depression affects many individuals after parturition, and selective serotonin reuptake inhibitors (SSRIs) are often used as the first-line treatment; however, both SSRIs and lactation are independently associated with bone loss due to the role of serotonin in bone remodeling.
View All Related Papers